p.106 抽出テキスト

A/C mutation carriers. Eur J Heart Fail 2013;15:376–384. https://doi.org/10.1093/ eurjhf/hfs191 440. Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol 2016;68:2299–2307. https://doi.org/10.1016/j.jacc.2016.08.058 441. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP, et al. Lamin A/ C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J 2017;39:853–860. https://doi.org/10.1093/eurheartj/ehx596 442. Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, et al. Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial. JACC Heart Fail 2018;6:689–697. https://doi.org/10.1016/j.jchf.2018.05.005 443. Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J 2018;39: 4277–4284. https://doi.org/10.1093/eurheartj/ehy626 444. Cikes M, Planinc I, Claggett B, Cunningham J, Milicic D, Sweitzer N, et al. Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC Heart Fail 2022;10:336–346. https://doi.org/10.1016/j.jchf.2022.01.018 445. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86–92. https:// doi.org/10.1016/j.ahj.2005.06.036 446. Aldaas OM, Lupercio F, Darden D, Mylavarapu PS, Malladi CL, Han FT, et al. Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. Am J Cardiol 2021;142:66–73. https://doi.org/10.1016/j.amjcard.2020.11.039 447. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol 2010;106:720–722. https://doi.org/10.1016/j.amjcard.2010.04.031 448. Camm CF, James CA, Tichnell C, Murray B, Bhonsale A, Te Riele ASJM, et al. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2013;10:1661–1668. https://doi.org/10.1016/j.hrthm.2013. 08.032 449. Saguner AM, Brunckhorst C, Duru F. Atrial arrhythmias in arrhythmogenic cardiomyopathy: at the beginning or at the end of the disease story? Reply. Circ J 2015;79:447. https://doi.org/10.1253/circj.CJ-14-1234 450. Müssigbrodt A, Knopp H, Efimova E, Weber A, Bertagnolli L, Hilbert S, et al. Supraventricular arrhythmias in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy associate with long-term outcome after catheter ablation of ventricular tachycardias. Europace 2018;20:1182–1187. https://doi.org/10.1093/europace/ eux179 451. Saguner AM, Ganahl S, Kraus A, Baldinger SH, Medeiros-Domingo A, Saguner AR, et al. Clinical role of atrial arrhythmias in patients with arrhythmogenic right ventricular dysplasia. Circ J 2014;78:2854–2861. https://doi.org/10.1253/circj.CJ-14-0474 452. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2019;9:CD005049. https://doi.org/10.1002/14651858. CD005049.pub4 453. Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 2018;25: 86–92. https://doi.org/10.1080/13506129.2018.1449744 454. Donnelly JP, Sperry BW, Gabrovsek A, Ikram A, Tang WHW, Estep J, et al. Digoxin use in cardiac amyloidosis. Am J Cardiol 2020;133:134–138. https://doi.org/10.1016/j. amjcard.2020.07.034 455. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993;104:618–620. https://doi.org/10.1378/chest.104.2.618 456. Yang YJ, Yuan JQ, Fan CM, Pu JL, Fang PH, Ma J, et al. Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of 1 and without anticoagulant therapy. Heart Vessels 2016;31:1148–1153. https://doi.org/10.1007/s00380-015-0718-5 457. Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart 2017;103: 1496–1501. https://doi.org/10.1136/heartjnl-2016-310720 458. Hirota T, Kubo T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort – results from Kochi RYOMA study. Circ J 2019;83:1747–1754. https://doi.org/10.1253/circj.CJ-19-0186 459. Tsuda T, Hayashi K, Fujino N, Konno T, Tada H, Nomura A, et al. Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation. Heart Rhythm 2019;16:829–837. https://doi.org/10.1016/j.hrthm. 2018.11.029 460. Lozier MR, Sanchez AM, Lee JJ, Donath EM, Font VE, Escolar E. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review. J Atr Fibrillation 2019; 12:2207. https://doi.org/10.4022/jafib.2207 461. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. Aging (Albany NY) 2020;12:24219–- 24227. https://doi.org/10.18632/aging.104133 462. Komatsu J, Imai RI, Nakaoka Y, Nishida K, Seki SI, Kubo T, et al. Importance of paroxysmal atrial fibrillation and sex differences in the prevention of embolic stroke in hypertrophic cardiomyopathy. Circ Rep 2021;3:273–278. https://doi.org/10.1253/circrep. CR-20-0101 463. Donnellan E, Elshazly MB, Vakamudi S, Wazni OM, Cohen JA, Kanj M, et al. No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol 2019;5:1473–1474. https:// doi.org/10.1016/j.jacep.2019.10.013 464. El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 2019;73:589–597. https://doi.org/10.1016/j.jacc.2018.10.079 465. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005;3:CD001927. https://doi.org/10.1002/ 14651858.CD001927 466. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 857–867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007 467. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007;3:CD006186. https://doi. org/10.1002/14651858.CD006186.pub2 468. Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 2008;94:1607–1613. https://doi.org/10.1136/hrt. 2007.135657 469. Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in nonvalvular atrial fibrillation: a network meta-analysis of 79 808 patients. Heart 2014;100: 396–405. https://doi.org/10.1136/heartjnl-2013-304347 470. Joundi RA, Cipriano LE, Sposato LA, Saposnik G; Stroke Outcomes Research Working Group. Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis. Stroke 2016;47:1364–1367. https:// doi.org/10.1161/STROKEAHA.115.012609 471. Nielsen PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep 2016;6:27410. https://doi.org/10.1038/srep27410 472. Shin SY, Han SJ, Kim JS, Im SI, Shim J, Ahn J, et al. Identification of markers associated with development of stroke in “clinically low-risk” atrial fibrillation patients. J Am Heart Assoc 2019;8:e012697. https://doi.org/10.1161/JAHA.119.012697 473. Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, Sriratanasathavorn C, Pooranawattanakul S, Punlee K, et al. A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 2003;86:S8–16. 474. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006;27:216–221. https://doi.org/10.1093/ eurheartj/ehi583 475. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006;48:2340–2347. https://doi.org/10.1016/j.jacc.2006.08.037 476. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006;354: 934–941. https://doi.org/10.1056/NEJMoa050955 477. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118: 2498–2505. https://doi.org/10.1161/CIRCULATIONAHA.108.772582 478. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 2009;20:22–28. https://doi.org/10.1111/j.1540-8167.2008. 01275.x 479. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010;303:333–340. https://doi.org/10.1001/jama.2009.2029 480. Pappone C, Vicedomini G, Augello G, Manguso F, Saviano M, Baldi M, et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol 2011;4: 808–814. https://doi.org/10.1161/CIRCEP.111.966408 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026